SCHEMBL29619113

SCHEMBL29619113

COCCNCCOc1ccc(NC(=O)C2(F)CC2)cc1-c1c(C)noc1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 2/20 0.43
AXL P30530 2/20 0.43
HTR2A P28223 2/20 0.40
CYP3A4 P08684 3/20 0.39
TSHR P16473 2/20 0.39
HSD17B10 Q99714 2/20 0.39
CYP2C9 P11712 1/20 0.39
FFAR1 O14842 2/20 0.38
HTR2C P28335 1/20 0.38
CYP1A2 P05177 3/20 0.38
CLK4 Q9HAZ1 2/20 0.38
ALOX15 P16050 1/20 0.38
CREBBP Q92793 1/20 0.38
KDM4E B2RXH2 1/20 0.37
HTT P42858 1/20 0.37
BRD4 O60885 1/20 0.37
BRD2 P25440 1/20 0.37
BRD3 Q15059 1/20 0.37
MAPT P10636 3/20 0.37
USP2 O75604 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31677943 0.88 HTR2A (0.41) METAXLHTR2AHTR2CKDM4E
SCHEMBL29619057 0.88 MET (0.44) METAXLHTR2ATSHRFFAR1
SCHEMBL29619012 0.85 GABRA5 (0.41) HTR2ACYP3A4TSHRHSD17B10CYP2C9
SCHEMBL29619043 0.83 HTR2A (0.50) HTR2AHTR2C
SCHEMBL29619052 0.83 HTR2A (0.48) HTR2AHTR2C
SCHEMBL29619126 0.81 MET (0.40) METAXLHTR2ACYP3A4TSHR
SCHEMBL29619029 0.78 MET (0.40) METAXLFFAR1
SCHEMBL24398709 0.77 MET (0.41) METAXLCREBBPKDM4EHTT
SCHEMBL29619028 0.77 FLT3 (0.41) METAXLHTR2AHTR2CCREBBP
SCHEMBL29619145 0.77 MET (0.41) METAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376090-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2024-11-14 US disclosed
EP-4236942-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2023-09-06 EP disclosed
WO-2022093850-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2022-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376090-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO HTR2A, HTR5A, HTR1A MET 4151/4885AXL 3793/4885HTR2A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.